MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
A phase 2 trial of durvalumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Centre Hospitalier Universitaire de Besancon, now recruiting.
Overview
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma is a phase 2, randomised interventional study registered as NCT07036380 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 75 participants, started 2025-12-22 and due to reach its primary completion in 2028-11. Interventions recorded: MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab. Conditions listed: Advanced Biliary Tract Carcinoma. Gallbladder cancer is named in the registry entry: "2. Histologically confirmed biliary tract carcinoma: intra/extrahepatic cholangiocarcinoma (note that gallbladder carcinoma are not eligible)". Sites: France. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSafety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialAlternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialDurvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.